Pharma BD Deal Intelligence
A joint venture that let GSK and Pfizer merge OTC portfolios (Advil, Sensodyne, Centrum, Panadol) into the category's largest player, with GSK holding 68% control against Pfizer's 32%. The 2022 Haleon spinoff proved the combined business was built to stand alone, not just to bulk up a balance sheet.
Pfizer, GlaxoSmithKline consumer healthcare merger to create over the counter drug giant, with GSK holding 68% and Pfizer 32%.
GlaxoSmithKline and Pfizer completed a transaction in 2019 to combine their consumer healthcare businesses into a joint venture, which was later spun off as…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
GSK and Pfizer combined their consumer healthcare businesses into a new joint venture, creating the world's largest OTC consumer healthcare company with ~$12.7B in combined annual sales. GSK contributed its consumer healthcare business and retained a 68% stake; Pfizer contributed its consumer healthcare business for a 32% equity stake. Pfizer received board representation (3 of 9 seats). The JV expected $650M in peak cost synergies. GSK later demerged the business as Haleon plc in July 2022.
$50.0B Global consumer healthcare/OTC market
Consumer healthcare encompasses OTC medications, oral care, vitamins/supplements, and wellness products. The GSK-Pfizer JV combined leading brands (Advil, Sensodyne, Centrum, Voltaren) and was later spun off as Haleon in 2022.
Haleon (Sensodyne, Advil, Centrum, Theraflu), J&J Consumer (Tylenol, Motrin), Bayer Consumer (Aleve, Claritin), Reckitt (Mucinex, Gaviscon), P&G Health (Vicks, Pepto). Key trend: premiumization and digital health integration.
$50.0B Global consumer healthcare/OTC market
Consumer healthcare encompasses OTC medications, oral care, vitamins/supplements, and wellness products. The GSK-Pfizer JV combined leading brands (Advil, Sensodyne, Centrum, Voltaren) and was later spun off as Haleon in 2022.
Haleon (Sensodyne, Advil, Centrum, Theraflu), J&J Consumer (Tylenol, Motrin), Bayer Consumer (Aleve, Claritin), Reckitt (Mucinex, Gaviscon), P&G Health (Vicks, Pepto). Key trend: premiumization and digital health integration.
$50.0B Global consumer healthcare/OTC market
Consumer healthcare encompasses OTC medications, oral care, vitamins/supplements, and wellness products. The GSK-Pfizer JV combined leading brands (Advil, Sensodyne, Centrum, Voltaren) and was later spun off as Haleon in 2022.
Haleon (Sensodyne, Advil, Centrum, Theraflu), J&J Consumer (Tylenol, Motrin), Bayer Consumer (Aleve, Claritin), Reckitt (Mucinex, Gaviscon), P&G Health (Vicks, Pepto). Key trend: premiumization and digital health integration.
$50.0B Global consumer healthcare/OTC market
Consumer healthcare encompasses OTC medications, oral care, vitamins/supplements, and wellness products. The GSK-Pfizer JV combined leading brands (Advil, Sensodyne, Centrum, Voltaren) and was later spun off as Haleon in 2022.
Haleon (Sensodyne, Advil, Centrum, Theraflu), J&J Consumer (Tylenol, Motrin), Bayer Consumer (Aleve, Claritin), Reckitt (Mucinex, Gaviscon), P&G Health (Vicks, Pepto). Key trend: premiumization and digital health integration.
GSK and Pfizer combined consumer health into JV valued at ~$12.7B. GSK 68%, Pfizer 32%. Leading OTC brands across 120 markets.
Combined business reported ~GBP 10B annual sales across 120 markets in FY2020. Reflects financial performance following GlaxoSmithKline plc's $12.7B acquisition of Pfizer Inc. (Consumer Healthcare Division).
GSK spun off consumer health as Haleon at ~GBP 30.5B ($36.4B) market cap. Part of GlaxoSmithKline plc's $12.7B deal to acquire Pfizer Inc. (Consumer Healthcare Division).
Pfizer sold entire remaining Haleon stake for GBP 2.5B ($3.24B), completing exit from consumer health.
GSK-Pfizer JV combined portfolios, grew to GBP 10.4B revenue, spun off as Haleon at $36B+ valuation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) (this deal) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
| GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. | 2007 | $1.6B | 47 |
← Browse all deals · How we score deals
More: 2018 deals · GlaxoSmithKline plc deals · Other deals